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Introduction
Clinical presentation of schizophrenia varies among individuals, but in general is characterized by positive (hallucinations, delusions), negative (social withdrawal), and disorganization symptoms, cognitive impairments, altered brain structure and function, and severe deficits in global and social functioning. There is a generalized cognitive impairment, as well as specific deficits across cognitive domains including processing speed, attention, working memory, verbal memory, and executive functioning, that are present as early as the pre-morbid state during childhood and persist through chronic stages of illness (Lewandowski et al., 2011) . There is consistent evidence from schizophrenia neuroimaging studies for ventricular enlargement, reduced gray matter volume of cortical and subcortical brain regions, and reduced white matter volume and fractional anisotropy of predominantly fronto-temporal tracts (Bora et al., 2011; Haijma et al., 2013; Shenton et al., 2001 ; van Erp et al., 2016) . Unaffected relatives of schizophrenia patients exhibit milder cognitive deficits and brain structural abnormalities (Boos et al., 2007; Keshavan et al., 2010; Thermenos et al., 2013) , suggesting these abnormalities are risk factors for the disorder rather than secondary effects. The molecular mechanisms underlying these brain abnormalities are only beginning to be unraveled, which has hindered the identification of rational targets for developing better treatments.
A practical approach for elucidating the disease biology is identifying genes that confer risk and characterizing their function within the brain.
It is long known that schizophrenia has a large genetic component, with heritability between 64 and 81% (Lichtenstein et al., 2009; Sullivan et al., 2003) . Genome-wide association studies (GWAS) of schizophrenia case/control datasets by the Psychiatric Genomics Consortium (PGC) have identified over 100 chromosomal loci that have genome-wide significant evidence for association (PGC Schizophrenia Working Group, 2014) . GWAS results indicate that schizophrenia is a polygenic disorder, for which thousands of common genetic variants with modest individual effects act in aggregate to increase disease liability (Psychosis Endophenotypes International Consortium et al., 2014; Purcell et al., 2009; Ripke et al., 2013) . Rare variants further contribute to schizophrenia liability (CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium; Psychosis Endophenotypes International Consortium, 2017; Malhotra and Sebat, 2012) .
A promising approach to translate these genetic findings into an understanding of the neural processes involved in schizophrenia is to evaluate their relevance to disease endophenotypes (Gottesman and Gould, 2003) . In this context, cognitive measures have a moderate to high heritability (h 2 = 0.2-0.7) (Seidman et al., 2015; Stone and Seidman, 2016) , while volumetric and diffusion brain measures are highly heritable (h 2 = 0.6-0.8) (Blokland et al., 2012 (Blokland et al., , 2017 . Common genetic variation (based on SNPs) explains a substantial proportion of this heritability, estimated at h 2 = 0.3-0.4 for cognitive (Hatzimanolis et al., 2015; Robinson et al., 2015) and brain volume phenotypes . Moderate to high genetic correlations between schizophrenia and cognitive and brain structural phenotypes (r g = 0.5-0.8) suggest a partially shared genetic etiology (Blokland et al., 2017; Bohlken et al., 2016; Lee et al., 2016) . Indeed, polygenic risk for schizophrenia is significantly associated with prefrontal inefficiency during working memory performance in patients and controls (Walton et al., 2013a; Walton et al., 2013b) , as well as lower cognitive performance among healthy populations (Germine et al., 2016; Hubbard et al., 2016; Lencz et al., 2014; Liebers et al., 2016) and schizophrenia patients . Specific genetic risk variants have also been associated with altered cognition and brain structure among patients (Donohoe et al., 2010 (Donohoe et al., , 2013 Lencz et al., 2010; Martin et al., 2015; Wassink et al., 2012; Yeo et al., 2014) although some studies are negative (van Scheltinga et al., 2013) , possibly due to the use of small samples that are prone to inconsistent results. Analyses of large, well-phenotyped samples consisting of both psychosis patients and control individuals will be important for clarifying the role of genetic risk variants in brain abnormalities relevant to illness.
With this in mind, the GENUS Consortium aims to improve knowledge of the contribution of genetic variation to schizophrenia brain abnormalities by investigating relevant brain traits in a large, comprehensively phenotyped sample collection. The GENUS Consortium draws upon the efforts of sixteen research groups that have previously collected samples consisting of psychosis patients (predominantly schizophrenia), unaffected controls, and/or unaffected familial high-risk (FHR) individuals assessed for neuropsychological function and/or brain structure, all of which have genome-wide SNP data or genomic DNA. Assembly of these samples into one harmonized collection substantially increases the statistical power compared to the individual samples alone. The large, well-phenotyped GENUS sample collection provides a prime opportunity to investigate the genetic basis of brain abnormalities in psychosis in order to gain insight into the underlying neural mechanisms. The purpose of this article is to describe the design, composition, and data components of the sample collection, while subsequent articles will focus on data analyses.
Methods

Collection of samples
Research groups that had previously collected samples for the purpose of schizophrenia studies were identified from the psychiatric genetics community and publications. Criteria for inclusion were: availability of SNP genotype data or genomic DNA, as well as demographic, neuropsychological and/or magnetic resonance imaging (MRI) data, and, for patients, clinical data.
Informed consent and ethics approval
The lead principal investigator for each sample verified approval from their institutional ethics committee for sharing human subject data. All research participants provided written informed consent (or legal guardian consent and subject assent). Ethics approval for the GENUS Consortium study at the central site was obtained from the Partners Healthcare (USA) Institutional Review Board. All data were anonymized prior to transfer to the central site.
Clinical and demographic data
For demographic data, all research groups had collected data on age at recruitment, sex, and education level, and most groups had also collected data on socioeconomic status and handedness. Clinical data were available for patients and, for some samples, FHR individuals. All site-specific clinical variables were renamed according to a common variable naming convention. Raw data underwent quality control analyses at the central site for expected value ranges and outliers. To enable comparison across sites, we computed basic descriptives (means and standard deviations for quantitative variables; frequency tables for categorical variables) and plotted histograms to check for unexpected differences in data distributions. Antipsychotic medication dosages, both current and lifetime, where available, were converted to chlorpromazine equivalents based on published dosage equivalence estimates (Gardner et al., 2010; Woods, 2003) .
Neuropsychological data
The specific neuropsychological tests ranged across samples, although all research groups administered tests within the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus cognitive battery (Nuechterlein et al., 2008) or tests with similar design and scoring. We therefore focused on MATRICS tests and tests that measure similar cognitive constructs as the MATRICS tests. Additionally, we included visuospatial ability and verbal ability tests, as most groups administered these tests. All site-specific test variables were renamed according to a common variable naming convention. The raw data from each test were checked for errors by calculating descriptive statistics and visualizing data distributions for each study sample. Premorbid IQ was estimated from reading tests (or vocabulary if reading tests were not available), and current IQ from Wechsler Adult Intelligence Scale (WAIS) subtests (see Supplementary Materials).
Neuroimaging data
For those research groups that acquired MRI scans, we required 1.5 or 3 Tesla field strength, and availability of control scans in order to normalize the imaging data. We imposed no restrictions on the scanner vendor or model. As an initial assessment of quality, a subset of 12 scans from each sample (3 male patients, 3 female patients, 3 male controls, 3 female controls) were visually inspected for consistent artifacts using 3DSlicer (http://www.slicer.org; Fedorov et al., 2012) , including partial brain coverage, wrap-around and motion artifacts, and gross signal/contrast inhomogeneity. Further quality control analyses were carried out upon receipt of the full dataset and will be described elsewhere.
SNP genotype data
Each research group provided raw SNP array genotype data, when available, or genomic DNA extracted from whole blood, buffy coat or saliva (≥2 ng/μL) that we genotyped on the Illumina Infinium PsychArray. Although most participants had self-reported ancestry information, we assigned ancestry by merging genotype call data from each sample with the 1000 Genomes Reference Panel (Sudmant et al., 2015; The 1000 Genomes Project Consortium et al., 2015 , and applying multidimensional scaling using Plink software (Purcell et al., 2007) to extract ancestry principal components. Model-based clustering (R function 'Mclust') was applied to classify participants into ancestral populations as defined by the 1000 Genomes Reference Panel. Basic quality control analyses of raw genotype data consisted of removing unplaced SNPs and confirming consistency between reported sex and X chromosome genotype.
Statistical analyses
Quantitative demographic data from patient, control, and FHR groups were compared using ANOVA. Chi-square tests compared the relative proportions of males/females, ancestral populations, and handedness across groups. For all statistical tests, an uncorrected alpha of 0.05 was applied.
Results
Central data management
Sixteen research groups contributed data from 19 samples consisting of 5199 patients, 4877 controls, and 725 FHR participants (unaffected relatives of psychosis patients), totaling 10,801 participants. Table 1 lists the data from each sample that was provided to the central site (Massachusetts General Hospital). Details for each data modality are provided in the sections below. Each research group provided the central site with detailed sample information (see Supplementary Materials), including recruitment (source, target diagnosis, illness stage [e.g. first-episode sample]), inclusion/exclusion criteria (ranges of age, IQ, and years of education; substance and medication use, MRI contraindications), and data modalities, which the central site reviewed and obtained clarification as necessary. Some samples have been previously contributed to other research consortia or the data made available in repositories (see Supplementary Materials). Table 2 shows the demographic and clinical characteristics of the 19 samples. The patient diagnoses consist of 76.4% schizophrenia, 8.9% schizoaffective disorder (SAD), 1.8% schizophreniform disorder (SPD), 6.5% bipolar disorder with psychosis (BD), and 6.3% other psychoses.
Demographic and clinical characteristics of samples
Fourteen samples consist of controls and patients with a range of illness durations, except for one sample (GAP) consists of only first-episode patients and controls. Four of these 14 samples also contain FHR individuals. Two samples consist of FHR and controls, two samples consist of only patients, and one sample consists of only controls. Given the range of illness duration (b 1-58 years) and the inclusion of FHR participants, the sample collection has a wide age range (8-86 years). The sex composition is 56.5% male and 43.5% female. There are significant differences between the patient, control, and FHR groups in age (younger FHR), sex ratio (more male patients), years of education (fewer in patients), and ancestral population (all p b 1 × 10 −10 ; Table 2 ), but not in handedness. These differences must be adjusted in analyses, or matched subsets selected. The most common clinical data across the samples are the Positive and Negative Syndrome Scale (PANSS; 54.7% of patients) (Kay et al., 1987; Peralta and Cuesta, 1994) , Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1983) and Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen, 1984) (29.5% of patients), and Global Assessment of Functioning (GAF; 33.9% of patients) (American Psychiatric Association, 2000). Current or lifetime average dose of antipsychotic medication (chlorpromazine equivalents) (Gardner et al., 2010; Woods, 2003) is available for 63.8% or 27.6% of patients, respectively, and 21.2% of patients have both dosage estimates. Dosages are similar to other clinical samples (Eum et al., 2017; van Erp et al., 2016) , suggesting that this patient collection is representative of and generalizable to the clinical population.
Neuropsychological measures
All 19 samples have neuropsychological data from 4892 patients (75.6% schizophrenia, 9.4% SAD, 1.7% SPD, 6.8% BD, 6.5% other psychosis), 4370 controls, and 720 FHR individuals (9982 participants or 92.4% of sample; Table 1 ). The most common tests administered across the samples are shown in Table 3 , with highest overlap across samples for Digit Symbol Coding, Verbal Fluency, and Word List Learning. 3488  1549  3956  2337  703  2895  1866  1097  1644  3488  1452  388  N controls  3535  1116  2826  1410  1025  1080  3248  610  904  2519  1017  705  N FHR  396  196  280  119  381  79  347  76  89  384  82  177  N total  7419  2861  7062  3866  2109  4054  5461  1783  2637  6391  2551 Supplementary Table 3 provides detailed information on the specific tests and number of participants. There are substantial differences in the mean premorbid IQ and mean current IQ between diagnostic groups (both p b 1 × 10 − 10 ; Table 2 ). The mean premorbid and current IQ of controls and FHR individuals are higher than the population mean of 100, as previously reported by other psychosis studies (Hill et al., 2013; Seidman et al., 2015) . However, the difference of 10 IQ points between the GENUS patients and controls is consistent with the literature (Khandaker et al., 2011; Woodberry et al., 2008) . Among the controls, current IQ is notably higher than premorbid IQ. The high current IQ is predominantly driven by samples that used few (2-4) WAIS subtests, which may overestimate current IQ compared to samples that used many subtests (i.e., full-scale IQ) (Axelrod, 2002) . The higher current IQ may also be due to a ceiling effect, where the reading tests used to estimate premorbid IQ have a lower maximum score (~130) than WAIS subtests used to estimate current IQ (maximum 160).
Neuroimaging data
Thirteen samples have T1-weighted structural MRI scans from 1364 patients (74.4% schizophrenia, 7.9% SAD, 3.8% SPD, 5.3% BD, 8.6% other psychosis), 1520 controls, 379 FHR individuals (3263 participants or 30% of sample; Table 1 ). Quality evaluation of a subset of scans from each sample discounted systematic gross errors and indicated that all datasets are high quality. In addition to the T1-weighted acquisitions, 10 samples have diffusion-weighted MRI scans from 1931 participants, and 9 samples have T2-weighted structural scans from 1821 participants. Table 4 lists the scanners and primary scan parameters for each sample. Full scan acquisition parameters are provided in the Supplementary Materials.
SNP genotype data
As detailed in the Supplementary Materials, 15 of the 19 samples had previously acquired raw SNP genotype data from 7478 participants (69.2%). For 10 samples, only a proportion of participants had been genotyped. Four of the 19 samples had genomic DNA from 978 participants (9.1%), of which 947 (8.8%) participants had sufficient DNA quality and quantity for genotyping on the Illumina Infinium PsychArray at the central site. Table 1 lists the SNP arrays used for each sample. Supplementary Table 1 lists the number of genotyped participants in each sample and Supplementary Table 2 provides the demographic and clinical characteristics. Of the total 8425 participants with genotype data, 164 participants were excluded during quality control analyses due to low (b 98%) genotype call rate, resulting in 8261 participants with genotype data suitable for imputation (4099 patients, 3851 controls, 306 FHR). Further quality control and imputation procedures will be described elsewhere. The mean call rate across the cleaned dataset is 99.8% (range 99.3%-99.9%). The sample collection has 80% power to detect a genetic variant that explains 0.5% of the variance of a phenotype at a genome-wide significant alpha = 5 × 10 −8 .
The ancestry breakdown based on genotype data is 70.2% European (2835 patients, 2703 controls, 264 FHR), 19.5% East Asian (624 patients, 982 controls, 1 FHR), 7.3% African (454 patients, 111 controls, 35 FHR), 2.0% American (predominantly Latino; 138 patients, 28 controls, 3 FHR), and 1.0% other ancestry (53 patients, 27 controls, 3 FHR).
Discussion
This article provides a general description of the GENUS Consortium and its sample collection, which is the largest known dataset of psychosis patients, controls, and FHR individuals with data spanning genetics, clinical, cognitive and, for a subset, structural MRI and diffusion imaging. This dataset enables large-scale investigations of brain-based phenotypes. Due to data sharing restrictions of many of the individual samples, the full dataset is currently only available to external researchers through collaboration with GENUS Consortium members. The extent of data and large size of the GENUS dataset, as well as the breadth of expertise of the GENUS Consortium members, provide a host of opportunities for analyses. For example, examining sex differences in diseaserelated phenotypes is an important but often overlooked aspect of psychiatric studies (Goldstein et al., 2013) that can be addressed with this large, well-phenotyped sample collection. The GENUS Consortium differs in several aspects from other largescale efforts investigating the genetic architecture of cognition and neuroanatomy relevant to psychosis (e.g., COGENT, ENIGMA, B-SNIP, Brain Genomics Superstruct Project, Philadelphia Neurodevelopmental Cohort) (Franke et al., 2016; Germine et al., 2016; Holmes et al., 2015; Lee et al., 2016; Lencz et al., 2014; Tamminga et al., 2013) . A key difference is that many other studies do not have data for both cognition and brain structure modalities from the same participants. Bridging multiple brain phenotype modalities, as in the GENUS sample collection, is important for heterogeneous disorders such as schizophrenia that are defined by diverse symptoms and abnormalities whose relationships are mostly unknown. Another difference is the GENUS subject-level data are stored at the central site, allowing for stringent quality control and site comparability analyses, and the option for mega-analyses across the entire dataset, whereas some other studies are limited to meta-analysis of results generated by each site separately.
A major strength of the GENUS sample collection is the existence of extensive data across patients, controls, and FHR individuals that enable analyses of genetic effects in multiple diagnostic groups. While informative genetic findings are emerging from large healthy cohorts, this is currently lacking in psychosis cohorts, and it remains unclear whether genetic factors influencing brain structure and function in healthy cohorts have the same effect in psychiatric patients. The GENUS Consortium analyses will initially focus on relating schizophrenia genetic risk variants identified by prior GWAS with the cognitive and brain structural phenotypes available in this sample collection. While the ENIGMA Consortium did not detect significant effects of schizophrenia genetic risk variants on subcortical volumes in mixed diagnosis and healthy individuals (Franke et al., 2016) , a study of cortical thickness and surface area reported that a substantial proportion (30-45%) of the heritability is explained by schizophrenia genetic risk variants . This suggests that some brain structural measures may be more genetically related to schizophrenia than others, or that genetic relationships differ in diseased and healthy brain. In addition, GWAS of cognitive performance and brain regional volumes have detected novel genetic associations (Adams et al., 2016; Davies et al., 2015; Hibar et al., 2015; Trampush et al., 2017) that could be further investigated in the GENUS sample collection.
Regarding genetic analyses, the GENUS sample collection is best suited for characterizing SNPs, polygenic factors, and pathways identified by GWAS, such as the PGC GWAS mega-analyses (PGC Schizophrenia Working Group, 2014), for effects on brain-based phenotypes, or replicating findings from other genetic studies of cognition or brain structure. Due to the small effect sizes of common genetic variants, our dataset is not well powered for GWAS discovery. SNP-based heritability approaches (e.g., GCTA) require approximately 4000 subjects for 80% power to estimate heritability as low as 20% (Visscher et al., 2014) , a reasonable assumption for cognitive and brain volume traits (Franke et al., 2016; Trampush et al., 2017) ; therefore, some of our phenotypes (e.g. letternumber span tests, WAIS Digit Symbol Coding) are suitable for this approach. Rare variant association studies require enormous samples for adequate statistical power (Auer and Lettre, 2015; Zuk et al., 2014) , therefore our dataset is not sufficient on its own for such analyses. The availability of multiple phenotypes enables a breadth of analyses, with the caveat that significance thresholds must be adjusted for multiple testing, although accounting for correlations between phenotypes and other data reduction methods could allow for more lenient thresholds. The statistical power of our dataset could also be maximized by merging phenotypes into one phenotype, such as Spearman's 'g', in which data from many neuropsychological tests are used to derive a single measure of general cognitive ability (Spearman, 1904) .
There are considerable challenges to combining data acquired by many research groups. The heterogeneity in the data collected and the protocols used by each group requires careful harmonization of the data to maximize comparability between the samples and minimize confounds. Our harmonization approaches will be described in greater detail in subsequent data-based articles. Briefly, we are applying methods that use controls from each sample to standardize the data (i.e., generate Z scores), as has been reported for neuropsychological data (Toulopoulou et al., 2010) and structural MRI data (Segall et al., 2009; Wilke et al., 2014) . Further, variability in multi-site imaging data due to different scanner models and field strengths, acquisition protocols, and image segmentation methods (Han et al., 2006) can be minimized by processing all scans using a consistent segmentation routine, which enables detection of subtle effects (Fennema-Notestine et al., 2007) , including gray matter loss in schizophrenia datasets (Segall et al., 2009) . Regarding clinical data, positive and negative symptom data can be converted between the PANSS and SANS/SAPS, the most common clinical scales in our dataset, using regression-based equations (van Erp et al., 2014) . As for the limited medication dosage information of our dataset, this can be addressed partially by confirming findings from the full cohort in the subset with medication data to rule out medication confounds. We are harmonizing the genotype data from various SNP arrays by imputing genotypes based on a reference panel to generate a common set of SNPs across all samples, an accepted approach in the field (PGC Schizophrenia Working Group, 2014). Although heterogeneous data collected by multiple sites is not ideal, the large volume of available legacy data with deep phenotypic and genotype information warrants maximizing its use by generating one merged dataset that has far greater statistical power than the individual samples.
In summary, the GENUS Consortium sample collection is a valuable resource that builds upon previous efforts by individual research groups and complements other psychosis datasets. This high-powered sample collection integrates measures of brain structure, cognition, and genetics for studying the biological basis of psychosis through original analyses and collaborative replication studies. There will be the opportunity for multiple publications from these data, including articles focusing on harmonization and genetic analyses of the cognitive data and imaging data, and publications that incorporate multi-modal data. The rich phenotypic data are expected to provide new insights into neural functions that are disrupted in psychosis.
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